好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Detection of pathology sensitive multimodal MRI measures in Theiler’s Murine Encephalomyelitis Virus Model of Chronic Demyelination
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
134

To investigate temporal brain region specific changes in MRI measures of Theiler’s Murine Encephalomyelitis Virus (TMEV) mice model of chronic demyelination using  9.4T brain MRI imaging.

To investigate temporal brain region specific changes in MRI measures of Theiler’s Murine Encephalomyelitis Virus (TMEV) mice model of chronic demyelination using  9.4T brain MRI imaging.

Two groups of mice (TMEV (n=6) or saline (n=6) intracerebrally injected) were weekly clinically monitored for 26 weeks, starting at 10 weeks post induction (wPI) and scanned with 9.4T MRI. Atlas registration and region segmentation was used to extract MRI measures from basal ganglia, corpus callosum, cortex, and thalamus. White matter (WM) structures, medial corpus callosum (CC), internal capsules (IC), fimbria (Fr) and anterior commissure (AC), were manually labeled to extract voxel-wise mean DTI fractional anisotropy (FA) and mean diffusivity (MD) values.  Brain volume and quantitative susceptibility mapping (QSM) changes were also serially assessed.

Significant differences in DTI measures of TMEV in different WM structures were noted. Amongst all measured structures, Fr FA measures were trending low in acute phase when compared to saline brains starting at 3 wPI, leading to a significant difference at 22 wPI. Similarly, IC FA value was significantly lower at 22 wPI. After a phase of growth driven volume increase in cortex and CC, TMEV brain regions exhibited a significant volume decrease between 10 to 18 wPI. Brain atrophy was associated with an increase in clinical disability scores and abnormal changes in QSM.

Early DTI FA changes are associated with acute inflammation and early demyelination in the TMEV model of MS. Chronic demyelination and axonal loss phase of TMEV is associated with development of brain atrophy and abnormal susceptibility. Further MRI-histology studies are warranted.

Authors/Disclosures
Ravendra Dhanraj
PRESENTER
Ravendra Dhanraj has nothing to disclose.
Suyog U. Pol, PhD (University At Buffalo - CTRC) Dr. Pol has nothing to disclose.
Ely G. Cuberos Paredes (University At Buffalo, Neuroscience Program) Ms. Cuberos Paredes has nothing to disclose.
No disclosure on file
Ferdinand Schweser, PhD (SUNY University At Buffalo) Dr. Schweser has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier.
Claire Modica An immediate family member of Claire Modica has received personal compensation for serving as an employee of Thermo Fisher Scientific. The institution of Claire Modica has received research support from Congressionally Directed Medical Research Programs. The institution of Claire Modica has received research support from Office of Naval Research.
No disclosure on file
No disclosure on file
Michael G. Dwyer III, MD, PhD (Buffalo Neurological Analysis Center) Dr. Dwyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Keystone Heart, Ltd. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Dwyer has received research support from Novartis. The institution of Dr. Dwyer has received research support from Keystone Heart, Ltd. The institution of Dr. Dwyer has received research support from Bristol Myers Squibb. The institution of Dr. Dwyer has received research support from Roche.
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center) The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.